skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Technetium-99m APD compared with technetium-99m MDP as a bone scanning agent

Abstract

The authors have investigated the possibilities of technetium-99m-(-3-aminohydroxypropylidene)-1-1-bisphosphonate ((/sup 99m/Tc)APD) as a bone scanning agent in 14 normal subjects and 28 patients. Similar studies in the same normal subjects and patients were carried out with /sup 99m/Tc-methylene-bisphosphonate ((/sup 99m/Tc)MDP). The compounds were labeled with /sup 99m/Tc by means of an electrolytical method; the free pertechnetate content was always under 1%. The (/sup 99m/Tc)APD T1/2 of the third component of the disappearance plasma curve in six normal subjects was 152 +/- 46 min (mean +/- s.d.), while the 24-hr whole-body retention (WBR) was 17.6% +/- 4.6. The (99mTc)MDP value of the 24-hr WBR was 28.6% +/- 3.9. The bone/soft-tissue ratio (B/ST) was investigated in eight control subjects on the eleventh thoracic and the fourth lumbar vertebrae. The B/ST ratios were similar for both APD and MDP studies. In 28 patients with suspected bone metastasis or primary bone disease, bone scintigraphy was carried out; both compounds showed similar findings and the same number of positive results. In five of these patients, the lesion/normal bone ratio was determined with values of 4.6 +/- 2.0 in APD studies and 4.8 +/- 2.3 with MDP. APD was also used in 126 patients; no adverse reactionsmore » were observed. The APD dose used i.v. for bone scanning was 200-fold less than those employed by mouth per day, for the treatment of bone disease for long periods. In our experience, APD appears to be an adequate agent for bone scintigraphy.« less

Authors:
; ; ; ; ;
Publication Date:
Research Org.:
Centro de Medicina Nuclear, Buenos Aires, Argentina
OSTI Identifier:
6125710
Resource Type:
Journal Article
Journal Name:
J. Nucl. Med.; (United States)
Additional Journal Information:
Journal Volume: 10
Country of Publication:
United States
Language:
English
Subject:
38 RADIATION CHEMISTRY, RADIOCHEMISTRY, AND NUCLEAR CHEMISTRY; PHOSPHONIC ACID ESTERS; RETENTION; RADIOPHARMACEUTICALS; CHEMICAL PROPERTIES; TECHNETIUM 99; COMPARATIVE EVALUATIONS; ELECTROLYSIS; ISOMERIC NUCLEI; PATIENTS; SKELETON; BETA DECAY RADIOISOTOPES; BETA-MINUS DECAY RADIOISOTOPES; BODY; DRUGS; ESTERS; HOURS LIVING RADIOISOTOPES; INTERMEDIATE MASS NUCLEI; ISOMERIC TRANSITION ISOTOPES; ISOTOPES; LABELLED COMPOUNDS; LYSIS; NUCLEI; ODD-EVEN NUCLEI; ORGANIC COMPOUNDS; ORGANIC PHOSPHORUS COMPOUNDS; ORGANS; RADIOISOTOPES; TECHNETIUM ISOTOPES; YEARS LIVING RADIOISOTOPES; 400702* - Radiochemistry & Nuclear Chemistry- Properties of Radioactive Materials

Citation Formats

Degrossi, O J, Oliveri, P, Garcia del Rio, H, Labriola, R, Artagaveytia, D, and Degrossi, E B. Technetium-99m APD compared with technetium-99m MDP as a bone scanning agent. United States: N. p., 1985. Web.
Degrossi, O J, Oliveri, P, Garcia del Rio, H, Labriola, R, Artagaveytia, D, & Degrossi, E B. Technetium-99m APD compared with technetium-99m MDP as a bone scanning agent. United States.
Degrossi, O J, Oliveri, P, Garcia del Rio, H, Labriola, R, Artagaveytia, D, and Degrossi, E B. 1985. "Technetium-99m APD compared with technetium-99m MDP as a bone scanning agent". United States.
@article{osti_6125710,
title = {Technetium-99m APD compared with technetium-99m MDP as a bone scanning agent},
author = {Degrossi, O J and Oliveri, P and Garcia del Rio, H and Labriola, R and Artagaveytia, D and Degrossi, E B},
abstractNote = {The authors have investigated the possibilities of technetium-99m-(-3-aminohydroxypropylidene)-1-1-bisphosphonate ((/sup 99m/Tc)APD) as a bone scanning agent in 14 normal subjects and 28 patients. Similar studies in the same normal subjects and patients were carried out with /sup 99m/Tc-methylene-bisphosphonate ((/sup 99m/Tc)MDP). The compounds were labeled with /sup 99m/Tc by means of an electrolytical method; the free pertechnetate content was always under 1%. The (/sup 99m/Tc)APD T1/2 of the third component of the disappearance plasma curve in six normal subjects was 152 +/- 46 min (mean +/- s.d.), while the 24-hr whole-body retention (WBR) was 17.6% +/- 4.6. The (99mTc)MDP value of the 24-hr WBR was 28.6% +/- 3.9. The bone/soft-tissue ratio (B/ST) was investigated in eight control subjects on the eleventh thoracic and the fourth lumbar vertebrae. The B/ST ratios were similar for both APD and MDP studies. In 28 patients with suspected bone metastasis or primary bone disease, bone scintigraphy was carried out; both compounds showed similar findings and the same number of positive results. In five of these patients, the lesion/normal bone ratio was determined with values of 4.6 +/- 2.0 in APD studies and 4.8 +/- 2.3 with MDP. APD was also used in 126 patients; no adverse reactions were observed. The APD dose used i.v. for bone scanning was 200-fold less than those employed by mouth per day, for the treatment of bone disease for long periods. In our experience, APD appears to be an adequate agent for bone scintigraphy.},
doi = {},
url = {https://www.osti.gov/biblio/6125710}, journal = {J. Nucl. Med.; (United States)},
number = ,
volume = 10,
place = {United States},
year = {Tue Oct 01 00:00:00 EDT 1985},
month = {Tue Oct 01 00:00:00 EDT 1985}
}